Form 4: Sana Biotech CFO Wyrick Reports Stock Transactions

Sana Biotechnology's Acting CFO, Susan D. Wyrick, reported the vesting of 3,400 restricted stock units and the subsequent sale of 873 shares for tax withholding.

Summary

• Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, Inc., reported transactions involving the company's common stock.
• On December 13, 2025, 3,400 restricted stock units (RSUs) vested, converting into 3,400 shares of common stock at an exercise price of $0.00.
• Following this, on December 15, 2025, 873 shares of common stock were disposed of at a price of $5.22 per share, likely for tax withholding purposes.
• After these transactions, Ms. Wyrick beneficially owns 180,790 shares of Sana Biotechnology, Inc. common stock directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related sales), which are neutral in terms of company-specific sentiment.

Positives

• The vesting of 3,400 restricted stock units represents a gain for the reporting person, Susan D. Wyrick, as these units converted into common stock at no cost.

Negatives

• The disposition of 873 shares of common stock at $5.22 per share for tax withholding reduces the reporting person's direct beneficial ownership.

Stakeholder Impact

• Minimal impact on shareholders as these are routine insider transactions related to executive compensation and do not indicate a change in company fundamentals or strategy.

Key Dates

Keywords

SANA, Form 4, insider transaction, restricted stock units, RSU vesting, executive compensation, stock sale, CFO, Sana Biotechnology